180 Life Sciences Corp
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
FRMM$2.88-5.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit No. | Description | Filed/ Furnished Herewith | Form | File No. | Exhibit | Filing Date |
|---|---|---|---|---|---|---|
| 2.1# | Asset Purchase Agreement dated September 29, 2024, by and among Elray Resources, Inc., as seller and 180 Life Sciences Corp., as purchaser | 8-K | 001-38105 | 2.1 | 10/03/2024 | |
| 3.1 | Certificate of Designations of 180 Life Sciences Corp. Establishing the Designations, Preferences, Limitations and Relative Rights of Its Series B Convertible Preferred Stock | 8-K | 001-38105 | 3.1 | 10/03/2024 | |
| 4.1 | Common Stock Purchase Warrant to purchase 3,000,000 shares of common stock dated September 30, 2024, granted by 180 Life Sciences Corp. to Elray Resources, Inc. | 8-K | 001-38105 | 4.1 | 10/03/2024 | |
| 4.2 | Form of Warrant to Purchase 1,900,138 Shares of Common Stock Granted on October 17, 2024 | 8-K | 001-38105 | 4.1 | 10/16/2024 | |
| 10.1 | Separation and Release Agreement dated September 5, 2024 and First Amendment to Separation and Release Agreement dated September 5, 2024, by and between Cannbiorex Pharma Ltd., 180 Life Sciences Corp. and Sir Marc Feldmann | 8-K | 001-38105 | 10.1 | 09/09/2024 | |
| 10.2 | Indemnity Agreement dated September 3, 2024 and effective September 5, 2024, between 180 Life Sciences Corp. and Sir Marc Feldmann | 8-K | 001-38105 | 10.2 | 09/09/2024 | |
| 10.3 | Form of Warrant Inducement Agreement, by and between the Company and Holder, dated October 16, 2024 | 8-K | 001-38105 | 10.1 | 10/16/2024 | |
| 10.4 | Financial Advisory Agreement, dated as of October 16, 2024, between A.G.P./Alliance Global Partners and the Company. | 8-K | 001-38105 | 10.2 | 10/16/2024 | |
| 31.1* | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act | X | ||||
| 31.2* | Certification of Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act | X | ||||
| 32.1** | Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act | X | ||||
| 32.2** | Certification of Principal Accounting Officer Pursuant to Section 906 of the Sarbanes-Oxley Act | X | ||||
| 101.INS* | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | X | ||||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema | X | ||||
| 101.CAL* | Inline XBRL Taxonomy Calculation Linkbase | X | ||||
| 101.DEF* | Inline XBRL Definition Linkbase Document | X | ||||
| 101.LAB* | Inline XBRL Taxonomy Label Linkbase | X | ||||
| 101.PRE* | Inline XBRL Definition Linkbase Document | X | ||||
| 104* | Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set | X | ||||
| * | Filed herewith. |
|---|
| ** | Furnished herewith. |
|---|
| # | Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K. A copy of any omitted schedule or Exhibit will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that 180 Life Sciences Corp., Inc. may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or Exhibit so furnished. |
|---|
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| 180 LIFE SCIENCES CORP. | ||
| Date: November 14, 2024 | By: | /s/ Blair Jordan |
|---|---|---|
| Blair Jordan Interim Chief Executive Officer (Principal Executive Officer) | ||
| Date: November 14, 2024 | By: | /s/ Omar Jimenez |
|---|---|---|
| Omar Jimenez Chief Financial Officer (Principal Financial and Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.